UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 7.

Vavricka, S R; Spigaglia, S M; Rogler, G; Pittet, V; Michetti, P; Felley, C; Mottet, C; Braegger, C P; Rogler, D; Straumann, A; Bauerfeind, P; Fried, M; Schoepfer, A M (2011). Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflammatory Bowel Diseases, 18(3):496-505.

Vavricka, S R; Schoepfer, A M; Bansky, G; Binek, J; Felley, C; Geyer, M; Manz, M; Rogler, G; de Saussure, P; Sauter, B; Scharl, M; Seibold, F; Straumann, A; Michetti, P (2011). Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflammatory Bowel Diseases, 17(7):1530-1539.

Schoepfer, A M; Vavricka, S R; Binek, J; Felley, C; Geyer, M; Manz, M; Rogler, G; de Saussure, P; Sauter, B; Seibold, F; Straumann, A; Michetti, P (2010). Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey. Inflammatory Bowel Diseases, 16(6):933-938.

Pittet, V; Juillerat, P; Michetti, P; Vader, J P; Burnand, B; Rogler, G; Beglinger, C; Seibold, F; Mottet, C; Felley, C; Gonvers, J J; Froehlich, F; et al; Braegger, C P (2010). Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. Alimentary Pharmacology & Therapeutics, 32(8):1007-1016.

Juillerat, P; Pittet, V; Vader, J P; Burnand, B; Gonvers, J J; de Saussure, P; Mottet, C; Seibold, F; Rogler, G; Sagmeister, M; Felley, C; Michetti, P; Froehlich, F; et al; Braegger, C P (2010). Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness. European Journal of Gastroenterology & Hepatology, 22(11):1352-1357.

Pittet, V; Juillerat, P; Mottet, C; Felley, C; Ballabeni, P; Burnand, B; Michetti, P; Vader, J P (2009). Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). International Journal of Epidemiology, 38:922-931.

Pache, I; Rogler, G; Felley, C (2009). TNF-alpha blockers in inflammatory bowel diseases: practical consensus recommendations and a user's guide. Swiss Medical Weekly, 139(19-20):278-287.

This list was generated on Sun Jul 23 04:59:49 2017 CEST.